Chemical inhibitors of FLJ40142 target various signaling pathways and molecular processes that play crucial roles in the protein's functional activity. Wortmannin and LY294002 are potent inhibitors of PI3K, which is an upstream regulator of the AKT pathway. Inhibition of PI3K by these chemicals leads to a decrease in AKT signaling, a pathway in which FLJ40142 is involved. The suppression of AKT activity curtails the downstream effects necessary for FLJ40142's function. Rapamycin exerts its inhibitory action by binding to and inhibiting mTOR, a central component of the cellular growth and proliferation signaling network that FLJ40142 is part of. By inhibiting mTOR, Rapamycin disrupts processes that are essential for FLJ40142's role in the cell, thereby inhibiting its function. Similarly, Triciribine directly targets the AKT pathway, upon which FLJ40142's functional activity relies, leading to FLJ40142 inhibition.
Moreover, Palbociclib, by inhibiting CDK4/6, indirectly affects the regulatory mechanisms controlling the cell cycle, thus impacting the pathways that FLJ40142 is implicated in. SP600125 and PD98059, which inhibit JNK and MEK respectively, disrupt the signaling cascades that could regulate FLJ40142 activity, resulting in its inhibition. SB203580's inhibition of p38 MAP kinase and U0126's targeting of MEK1/2 both lead to disruptions in the ERK pathway, which is potentially a regulatory pathway for FLJ40142, thereby inhibiting the protein's activity. Leflunomide, by inhibiting dihydroorotate dehydrogenase, affects pyrimidine synthesis, which is essential for cell division and consequently influences FLJ40142's role. Proteasome inhibitors, such as Bortezomib and MG132, impede the degradation pathways of proteins, potentially leading to the accumulation of regulatory proteins that control FLJ40142, thus inhibiting its function. Through these diverse but specific mechanisms, each chemical contributes to the inhibition of FLJ40142 by directly or indirectly disturbing the pathways and processes that FLJ40142 requires for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K which is upstream of AKT signaling, a pathway FLJ40142 is involved in, leading to reduced AKT activity and thus inhibiting FLJ40142. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Targets and inhibits PI3K, thereby preventing the activation of AKT pathway, which is necessary for FLJ40142 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to mTOR and inhibits its activity, which is crucial for downstream signaling that includes FLJ40142, leading to its functional inhibition. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Specifically inhibits the AKT pathway, which in turn is required for FLJ40142 functional activity, resulting in its inhibition. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibits CDK4/6, which are indirectly involved in the regulation of pathways necessary for FLJ40142 activity, leading to its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could be part of the signaling cascade that regulates FLJ40142 function, thereby inhibiting FLJ40142. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which is upstream of ERK pathway, a potential regulator of FLJ40142, thus inhibiting FLJ40142 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, potentially involved in the same pathway as FLJ40142, leading to inhibition of FLJ40142. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2 and consequently ERK pathway which may regulate FLJ40142, leading to inhibition of FLJ40142 function. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Inhibits dihydroorotate dehydrogenase, impacting pyrimidine synthesis, which is vital for cell division wherein FLJ40142 plays a role, thus inhibiting FLJ40142. |